ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
The
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.The New England journal of medicine · 2019Trial
- Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities.bioRxiv : the preprint server for biology · 2025Article
- PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials.Current oncology reports · 2025Review
- ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.The journal of liquid biopsy · 2025Article
- Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer.Cancer medicine · 2024Article
- In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.Journal of clinical pathology · 2024Article
- PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal InteractionCancer research communications · 2023Article
- Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.International journal of molecular sciences · 2023Review
- Advances in PARP Inhibitors for Prostate Cancer.Cancers · 2023Review
- Precision Medicine forCancers · 2022Review
- Synthetic Lethality in Ovarian Cancer.Molecular cancer therapeutics · 2021Review
- Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors.Cell death discovery · 2021Article
- Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.Journal of translational medicine · 2020Article
- Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.Scientific reports · 2020Article
- Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.International journal of cancer · 2020Article
- Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Drugs · 2020Review
- Synthetic Lethal Activity of Benzophenanthridine Alkaloids FromFrontiers in pharmacology · 2020Article
- Update on PARP Inhibitors in Breast Cancer.Current treatment options in oncology · 2018Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.